Comparison of renoprotective effects of febuxostat and allopurinol in hyperuricemic patients with chronic kidney disease.
Jang-Wook LeeKwang-Hoon LeePublished in: International urology and nephrology (2019)
Febuxostat seems to reduce serum uric acid level and to retard renal disease progression more effectively than allopurinol in hyperuricemic patients with CKD.